Eli Lilly & Company (Lilly) is an innovative R&D-driven biopharmaceutical company. We support the Commissions objectives to improve patient access in Europe and boost Europes competitiveness. The reform presents an opportunity to simplify, speed and future proof regulatory procedures to ensure new innovations in company pipelines reach patients.
ELC
Eli Lilly & Company
Company · Belgium · EU Transparency Register 04657143399-39
5
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #430 by legislative files engaged, a count of participation, not a measure of influence.
1.9
declared lobbying FTE
self-declared
€900K+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2010
in the register since
Declares membership of
- Eli Lilly and Company is a member of the following associations and bodies: European Federation of Pharmaceutical Ind…
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Registered as
- Eli Lilly and Company (Lilly)
- Head office
- Indianapolis, United states
- EU office
- Brusselles / Brussel
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Eli in PolicySpeak: request access →
Work at Eli Lilly & Company? so we know who speaks for it.
Their record over time
Eli Lilly & Company filed 5 positions between 26 Apr 2021 and 19 May 2026, across 3 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2021 · 1 filed2023 · 3 filed2026 · 1 filed
What they argued
Eli Lilly & Company (Lilly) is an innovative R&D-driven biopharmaceutical company. We support the Commissions objectives to improve patient access in Europe and boost Europes competitiveness. The reform presents an opportunity to simplify, speed and future proof regulatory procedures to ensure new innovations in company pipelines reach patients.
Eli Lilly & Company (Lilly) wishes to offer this solution-oriented reply for improving the EU medicines ecosystem, making life better for patients, and facilitating the EU’s leadership in life sciences. Future-proofed system Policies that enable adaptability and adequate resourcing will ensure that the EU regulatory system is efficient, effective, and competitive.
Eli Lilly welcomes the European Commission's (EC) commitment to strengthening CVD prevention through the Recommendation on CV health checks. CVD remains the leading cause of death in Europe. Tackling this burden requires an integrated approach, recognising CVD, diabetes, and obesity as interconnected conditions with common pathophysiological mechanisms.
Eli Lilly and Company (Lilly) is an innovative R&D-driven pharmaceutical company that unites caring with discovery to create medicines that make life better for people around the world. We welcome the opportunity to provide feedback to the Commission Proposal for a Directive on Urban Waste Water Treatment COM(2022)541 (UWWTD) and the accompanying Annex, impact assessment.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Eli Lilly & Company next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 38.
Is this your organization?
Everything on this page comes from Eli Lilly & Company’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.